Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vonicog alfa - Takeda

Drug Profile

Vonicog alfa - Takeda

Alternative Names: BAX 111; Recombinant von Willebrand factor; rVWF; SHP-677; TAK 577; VEYVONDI; VEYVONDI IU; Vonvendi

Latest Information Update: 29 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Delbruck Center for Molecular Medicine
  • Developer Takeda
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Von willebrand factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Von Willebrand disease

Most Recent Events

  • 09 Jan 2024 Phase-III clinical trials in Von Willebrand disease (Prevention, In children) in Ireland, Ireland, Norway, Sweden, Spain, France, France, Austria, Netherlands, Italy (IV) (EudraCT2020-003304-13, NCT05582993)
  • 15 Dec 2023 Takeda initiates an expanded-access programme for Von Willebrand Disease (In children, In adults, In the elderly) (IV) (NCT06173024)
  • 12 Oct 2023 The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopts positive opinion recommending approval of vonicog alfa for Von Willebrand disease (In adults, Prevention) in European Union (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top